Nile Pharmaceuticals results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit53.84 millionEGP · +158.4% vs the same period a year earlier
Total assets1.11 billionEGP · +28.2% vs the same period a year earlier
Shareholders' equity532 millionEGP · +17.8% vs the same period a year earlier
Operating cash flow70.21 millionEGP · +134.6% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q1 2024 was about 53.84 million EGP, up +158.4% from 20.84 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 1.11 billion EGP, and shareholders' equity about 532 million EGP.
- Operating cash flow for Q1 2024 was positive at 70.21 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit53.84 million20.84 million+158.4%
Gross profit113 million54.31 million+108.7%
Total assets1.11 billion863 million+28.2%
Total liabilities574 million411 million+39.6%
Shareholders' equity532 million452 million+17.8%
Total liabilities and equity1.11 billion863 million+28.2%
Operating cash flow70.21 million-203 million+134.6%
Investing cash flow-10.93 million-1.44 million−658.2%
Financing cash flow88.11 million195 million−54.8%
Net change in cash147 million-9.31 million+1682.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy